Latest Breaking News On - Christelle huguet - Page 6 : comparemela.com

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

PARIS, FRANCE, 7 December 2023 - Ipsen , a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our.

City ofUnited kingdomFrance generalUnited statesNicolas boglerAmy wolfDavid loewIpsen euronextAymeric le chatelierIoana piscociuBartek bednarzStewart campbellChristelle huguetMari scheiffeleCapital markets dayChief executive officer

Capital Markets Day 2023 - Ipsen Outlines Next Phase Of Growth & Transformation And Provides New Mid-Term Outlook

Capital Markets Day 2023 - Ipsen Outlines Next Phase Of Growth & Transformation And Provides New Mid-Term Outlook
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomFrance generalUnited statesAmy wolfChristelle huguetIoana piscociuIpsen euronextDavid loewNicolas boglerStewart campbellMari scheiffeleBartek bednarzAymeric le chatelierCapital markets dayChief executive officer

Ipsen Pharma: Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

Ipsen Pharma: Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomFrance generalUnited statesStefan klotterNicolas boglerStewart campbellIoana piscociuDavid loewChristelle huguetBartek bednarzIpsen euronextAmy wolfMari scheiffeleAymeric le chatelierCapital markets day

Ipsen Pharma: Ipsen confirms U S FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Ipsen Pharma: Ipsen confirms U S FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalUnited kingdomUnited statesIoana piscociuNicolas boglerStefan klotterKumagit heathcoteAnna gibbinsIpsen euronextAmy wolfChristelle huguetPascal prigentStephanie boyerEuropean medicines agencyUncertainties of the companyHead of research development

Elafibranor Granted Priority Review for Primary Biliary Cholangitis

The FDA has accepted for Priority Review the NDA for elafibranor for the second-line treatment of primary biliary cholangitis.

Christelle huguetDrug administrationHead of research developmentPriority reviewNew drug applicationItch numeric rating scale